 | This article contains content that is written like an advertisement. (September 2023) |
 | |
| Company type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | April 7, 2014 |
| Founder | Vivek Ramaswamy |
| Headquarters | London, United Kingdom |
Key people | Matt Gline (CEO) |
| Revenue |  US$125 million (2024) |
| US$4.24 billion (2024)[a] | |
| US$4.35 billion (2024)[a] | |
| Total assets | US$7.22 billion (2024)[a] |
| Total equity | US$6.45 billion (2024)[a] |
| Owner | Vivek Ramaswamy (10.5%) |
Number of employees | 908 (2024) |
| Website | roivant |
| Footnotes / references Financials as of 31 March 2024[update].[1][2] | |
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy[3]
- ^ a b "FY 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commisssion. 30 May 2024. Retrieved 16 June 2024.
- ^ "2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.
- ^ Hyatt, John (April 26, 2023). "How Rich Is Vivek Ramaswamy, The Longshot GOP Presidential Candidate Who Helped Take Down Don Lemon?". Forbes. Archived from the original on July 10, 2023. Retrieved July 10, 2023.
Cite error: There are <ref group=lower-alpha> tags or {{efn}} templates on this page, but the references will not show without a {{reflist|group=lower-alpha}} template or {{notelist}} template (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search